Clinical Trial Update: Testing the Use of Fulvestrant and Binimetinib Targeted Treatment for NF1 Mutation in Hormone Receptor-Positive Metastatic Breast Cancer (A ComboMATCH Treatment Trial) [Phase 2]

View source ↗

Summary

A Phase 2 ComboMATCH trial evaluating fulvestrant plus binimetinib for NF1-mutant, hormone receptor-positive metastatic breast cancer was terminated, with resul…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Hormone Receptor-positive Breast Cancer

Drugs mentioned

• Binimetinib (Mektovi) (binimetinib)
• Fulvestrant (Faslodex) (fulvestrant)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Anatomic Stage IV Breast Cancer AJCC v8, Metastatic HER2-Negative Breast Carcinoma | Phase 2 | Status: TERMINATED | Results posted: 2026-03-03